FocusCANCER IMMUNOLOGY

Developing combination immunotherapies against cancer that make sense

See allHide authors and affiliations

Science Immunology  02 Nov 2018:
Vol. 3, Issue 29, eaav1872
DOI: 10.1126/sciimmunol.aav1872

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Mechanistic preclinical studies provide a compelling case that combination immunotherapies that target the receptors PD-1 and GITR may demonstrate synergy in human cancer.

View Full Text